These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29110140)

  • 1. Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix
    Najafzadeh M; Garces JA; Maciel A
    Pharmacoeconomics; 2017 Dec; 35(12):1297-1310. PubMed ID: 29110140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder.
    Groessl EJ; Tally SR; Hillery N; Maciel A; Garces JA
    J Manag Care Spec Pharm; 2018 Aug; 24(8):726-734. PubMed ID: 30058980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of combinatorial pharmacogenomic testing for depression from the Canadian public payer perspective.
    Tanner JA; Davies PE; Overall CC; Grima D; Nam J; Dechairo BM
    Pharmacogenomics; 2020 Jun; 21(8):521-531. PubMed ID: 32301648
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of combinatorial pharmacogenomic guidance in treating psychiatric disorders.
    Benitez J; Cool CL; Scotti DJ
    Per Med; 2018 Nov; 15(6):481-494. PubMed ID: 30256179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of a Collaborative Care Depression and Anxiety Treatment Program in Patients with Acute Cardiac Illness.
    Celano CM; Healy B; Suarez L; Levy DE; Mastromauro C; Januzzi JL; Huffman JC
    Value Health; 2016; 19(2):185-91. PubMed ID: 27021752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of Electroconvulsive Therapy vs Pharmacotherapy/Psychotherapy for Treatment-Resistant Depression in the United States.
    Ross EL; Zivin K; Maixner DF
    JAMA Psychiatry; 2018 Jul; 75(7):713-722. PubMed ID: 29800956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomic test that predicts response to inhaled corticosteroids in adults with asthma likely to be cost-saving.
    Wu AC; Gay C; Rett MD; Stout N; Weiss ST; Fuhlbrigge AL
    Pharmacogenomics; 2015; 16(6):591-600. PubMed ID: 25880024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility.
    Bradley P; Shiekh M; Mehra V; Vrbicky K; Layle S; Olson MC; Maciel A; Cullors A; Garces JA; Lukowiak AA
    J Psychiatr Res; 2018 Jan; 96():100-107. PubMed ID: 28992526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of treatments for major depression in primary care practice.
    Lave JR; Frank RG; Schulberg HC; Kamlet MS
    Arch Gen Psychiatry; 1998 Jul; 55(7):645-51. PubMed ID: 9672056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of combinatorial pharmacogenomic testing for treatment-resistant major depressive disorder patients.
    Hornberger J; Li Q; Quinn B
    Am J Manag Care; 2015 Jun; 21(6):e357-65. PubMed ID: 26247576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine.
    Thompson AJ; Newman WG; Elliott RA; Roberts SA; Tricker K; Payne K
    Value Health; 2014; 17(1):22-33. PubMed ID: 24438714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of alternative treatments for depression in low-income women.
    Beil H; Beeber LS; Schwartz TA; Lewis G
    J Ment Health Policy Econ; 2013 Jun; 16(2):55-65. PubMed ID: 23999203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The costs and benefits of enhanced depression care to employers.
    Wang PS; Patrick A; Avorn J; Azocar F; Ludman E; McCulloch J; Simon G; Kessler R
    Arch Gen Psychiatry; 2006 Dec; 63(12):1345-53. PubMed ID: 17146009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
    Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
    J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic value of treating lumbar disc herniation in Brazil.
    Falavigna A; Scheverin N; Righesso O; Teles AR; Gullo MC; Cheng JS; Riew KD
    J Neurosurg Spine; 2016 Apr; 24(4):608-14. PubMed ID: 26654336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective.
    Osnabrugge RL; Magnuson EA; Serruys PW; Campos CM; Wang K; van Klaveren D; Farooq V; Abdallah MS; Li H; Vilain KA; Steyerberg EW; Morice MC; Dawkins KD; Mohr FW; Kappetein AP; Cohen DJ;
    Heart; 2015 Dec; 101(24):1980-8. PubMed ID: 26552756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seven-year cost-effectiveness of ProDisc-C total disc replacement: results from investigational device exemption and post-approval studies.
    Radcliff K; Lerner J; Yang C; Bernard T; Zigler JE
    J Neurosurg Spine; 2016 May; 24(5):760-8. PubMed ID: 26824587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating the Societal Benefits of THA After Accounting for Work Status and Productivity: A Markov Model Approach.
    Koenig L; Zhang Q; Austin MS; Demiralp B; Fehring TK; Feng C; Mather RC; Nguyen JT; Saavoss A; Springer BD; Yates AJ
    Clin Orthop Relat Res; 2016 Dec; 474(12):2645-2654. PubMed ID: 27699631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.